Form 4: Vaxcyte CEO Pickering Boosts Equity Holdings

Vaxcyte CEO Grant Pickering reported significant equity transactions, including the acquisition of restricted stock units and stock options, alongside shares disposed for tax obligations.

Summary

• Grant Pickering, Chief Executive Officer and Director of Vaxcyte, Inc. (PCVX), reported changes in his beneficial ownership.
• Acquired 105,110 shares of Common Stock underlying Restricted Stock Units (RSUs) on February 26, 2026, with a deemed price of $0.
• Acquired 175,698 Stock Options with an exercise price of $60 on February 26, 2026, with a deemed price of $0.
• Disposed of 2,863 shares of Common Stock on February 28, 2026, at $61.98 per share to cover applicable tax withholding obligations realized upon the vesting of RSUs.
• Disposed of 2,531 shares of Common Stock on March 2, 2026, at $61.98 per share to cover applicable tax withholding obligations realized upon the vesting of RSUs.
• Following these transactions, Pickering directly owns 500,624 shares of Common Stock and indirectly owns 136,215 shares through children's trusts.
• The RSUs vest as to 1/4 of the shares on September 7, 2026, and 1/8 of the shares every six months thereafter, subject to continuous service with the Issuer.
• The stock options vest as to 1/48 of the shares monthly, starting March 26, 2026, subject to continuous service with the Issuer, and expire on February 26, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. The acquisition of substantial equity awards (RSUs and stock options) by the CEO demonstrates continued commitment and alignment with shareholder interests, despite the routine tax-related share dispositions.

Positives

• Acquisition of 105,110 Restricted Stock Units (RSUs) aligns management's interests with shareholders.
• Acquisition of 175,698 stock options further incentivizes long-term performance and value creation.
• The vesting schedules for both RSUs and stock options are tied to continuous service, promoting management retention.

Negatives

• Disposition of 5,394 shares (2,863 + 2,531) of Common Stock at $61.98 to cover tax withholding obligations, while a standard practice, represents a reduction in direct ownership.

Future Outlook

The vesting schedules for the newly acquired Restricted Stock Units (RSUs) and stock options extend into the future, with RSUs vesting quarterly starting September 7, 2026, and stock options vesting monthly starting March 26, 2026, both contingent on continuous service. This indicates a long-term incentive structure for the CEO.

Industry Context

StockSavvy.ai notes that insider equity acquisitions, particularly by a CEO, are often viewed positively by the market as they signal management's confidence in the company's future prospects and align their financial interests with those of shareholders. The structure of these awards, with multi-year vesting, is typical for executive compensation in the biotechnology sector, aiming to retain key talent and incentivize long-term value creation.

Stakeholder Impact

• Shareholders: The acquisition of significant equity awards by the CEO aligns management's long-term interests with those of shareholders, potentially fostering greater confidence in the company's future performance.
• Employees: The CEO's continued commitment, as evidenced by these equity awards, may signal stability and a positive outlook for the company, potentially boosting employee morale.

Next Steps

• Continued vesting of 1/48 of stock options monthly, starting March 26, 2026.
• Continued vesting of 1/4 of RSUs on September 7, 2026, followed by 1/8 every six months thereafter.

Key Dates

Keywords

Vaxcyte, PCVX, Grant Pickering, Insider Transaction, Form 4, Restricted Stock Units, Stock Options, Equity Compensation, CEO, Director